Adamax vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Adamax | Cagrilintide |
|---|---|---|
| Mechanism | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |